# CITADEL-204 (NCT03144674)

> A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

No report yet. It can be ordered.

- Drugs tested: parsaclisib
- Indication: relapsed or refractory marginal zone lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03144674
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Incyte Corporation
- Conditions: Lymphoma
- Interventions: Parsaclisib
- Enrollment: 110
- Primary outcome: Objective Response Rate (ORR) Based on Lugano Classification Criteria

## Indexed commentary on CITADEL-204 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=citadel-204-nct03144674